Fig. 2From: TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancersCorrelation between TOP2A expression and PLD-Treatment Free Interval. a Cases showing TOP2A expression above 18% (mean value of this study) versus cases with TOP2A below cut-off limit. b Patients with TOP2A expression above 18% treated with PLD-monotherapy versus PLD-based polychemotherapyBack to article page